The wide-ranging expression of glutamate receptors in peripheral tissues suggests an unexpectedly wider role(s) of L -glutamate as an intercellular signaling molecule. However, the peripheral glutamatergic system is poorly understood, partly because the sites of L -glutamate signal appearance are less well characterized. Vesicular glutamate transporters (VGLUTs) are potential probes for the sites of vesicular storage and subsequent secretion of L -glutamate. In this study we raised specific polyclonal antibodies against two VGLUT isoforms, VGLUT1 and VGLUT2, and investigated their localization in peripheral tissues of rat. We detected the expression of either VGLUT1 or VGLUT2, or both, in pancreas, stomach, intestine, and testis. In pancreas, VGLUT1 and VGLUT2 are present in pancreatic polypeptide-containing secretory granules in F-cells in the islets of Langerhans. In stomach, VGLUT2 is abundant in the antrum and pylorus and is present in a subset of pancreatic polypeptide-containing cells. In intestine, VGLUT2 is abundant in the ileum and is co-localized with glucagon-like immunoreactive peptide and polypeptide YY (PYY). In testis, VGLUT2 is expressed and localized in the outer acrosomal membrane of spermatids, where KA1 and GluR5, kainate receptor subunits, are almost always localized. Taken together, these results strongly suggest the occurrence of a peripheral glutamatergic system in the gastroenteropancreatic system and testis. 
L -Glutamate is an excitatory chemical transmitter that plays an essential role in neuronal plasticity, behavior, learning, and memory in the central nervous system (Foster and Fagg 1984; Mayer and Westbrook 1987) . To use l -glutamate as a signaling molecule, neuronal cells have developed glutamatergic systems involving signal reception through glutamate receptors, signal termination through Na ϩ -dependent glutamate transporters, and signal output through vesicular storage and successive exocytosis of l -glutamate. Recent evidence indicates that various kinds of glutamate receptors are expressed throughout peripheral tissues, suggesting that l -glutamate functions as a chemical transmitter in these tissues Skerry and Genever 2001) . For example, pinealocytes, endocrine cells for melatonin, possess endogenous glutamatergic systems. The cells store l -glutamate in synapse-like microvesicles and secrete it on stimulation . The released l-glutamate may in turn bind to class II metabotropic glutamate receptors, causing inhibition of melatonin synthesis through an inhibitory cAMP cascade (Yamada et al. 1998 ). An excess amount of l-glutamate can be sequestered through a GLT-1-type plasma membrane glutamate transporter (Yatsushiro et al. 1997) . The islets of Langerhans, miniature endocrine organs that secrete hormones regulating the blood glucose concentration, constitute another example of a peripheral glutamatergic system. l -Glutamate is stored in glucagon-containing secretory granules in ␣ -cells and is secreted through exocytosis on low-glucose stimulation . These endocrine cells possess all components of a glutamatergic system. Therefore, these glutamatergic systems can be called peripheral glutamatergic systems Hayashi et al. 2001 Hayashi et al. ,2003 .
Vesicular glutamate transporters (VGLUTs) play an essential role in glutamate signal output through vesicular storage of l -glutamate (Otis 2001) . Thus far, three kinds of isoforms have been identified, i. e., VGLUT1 (Bellocchio et al. 2000; Takamori et al. 2000) , VGLUT2 (Bai et al. 2001; Fremeau et al. 2001; Hayashi et al. 2001; Herzog et al. 2001; Takamori et al. 2001; Varoqui et al. 2002) , and VGLUT3 (Fremeau et al. 2002; Gras et al. 2002; Schafer et al. 2002; Takamori et al. 2002) . VGLUTs appear to be potential and useful probes for exploring peripheral glutamatergic systems because their presence directly indicates sites for the l -glutamate signal. In fact, VGLUT2 is present in glucagon-containing ␣ -cells and in pancreatic polypeptide-containing F-cells and clonal islet cells Bai et al. 2003) . VGLUT1 is also expressed in a subpopulation of islet ␣ -cells . In ␣ -cells, VGLUT1 and VGLUT2 are localized with glucagon-containing secretory granules . VGLUT1 and VGLUT2 are also present in synapse-like microvesicles in pinealocytes Morimoto et al. 2003) , consistent with the glutamatergic nature of these cells.
In this study we investigated the expression and localization of VGLUT1 and VGLUT2 in non-neuronal cells of rat peripheral tissues using specific antibodies with special reference to pancreas, stomach, intestine, and testis. Because the GI contains more than 18 kinds of endocrine cells (Solcia et al. 1987) , we expected that some of these cells would exhibit a glutamatergic phenotype, as in the case of islets of Langerhans. The testis expresses glutamate receptors (Storto et al. 2001) , indicating that some cells are glutamatergic in nature. Here we show that VGLUT1 and VGLUT2 are present in pancreatic polypeptide-containing secretory granules of F-cells in the islets of Langerhans and that VGLUT2 is present in a subset of pancreatic polypeptide-containing stomach cells, L-cells containing glucagon-like immunoreactive peptide and PYY in ileum mucosa, and acrosomes of testicular spermatids. These results strongly suggest that l -glutamate functions as an intercellular or intracellular messenger in these peripheral tissues.
Materials and Methods

Animals
Male Wistar rats at 7-8 postnatal weeks were used throughout the study. All animal use procedures and care were in fully accordance with guidelines for the animal care at Okayama University.
Antibodies
DNA fragments encoding the C-terminal cytosolic regions of VGLUT1 (198 bp) (Ni et al. 1994 ) and VGLUT2 (270 bp) (Aihara et al. 2000) , which correspond to G509-Y560 and G500-S582, respectively, were amplified by PCR and then cloned into the EcoRI site of expression vector pGEX3X for VGLUT1 and pGEX4T-2 for VGLUT2 (Amersham Pharmacia Biotech; Piscataway, NJ) to form GST fusion plasmids. The expression plasmids were transformed to E. coli BL21, and the resultant transformants were cultured and harvested after induction with 1 mM isopropyl 1-thio-␤ -d -galactoside for 3 hr. The E. coli cells were suspended in 50 mM TrisHCl, pH 8.0, 50 mM NaCl, 1 mM EDTA, and 1 mM dithiothreito, and vigorously sonicated, and the resultant mixture was centrifuged. The supernatant was applied to a 1 ml glutathione-Sepharose 4B column (Amersham Pharmacia Biotech). The GST fusion peptides encoding G509-S560 for VGLUT1 and G500-Y582 for VGLUT2 were eluted by addition of the same buffer containing 16 mM reduced glutathione. The GST fusion proteins were injected into rabbits with complete adjuvant two times with a 2-week interval. Because the amino acid sequences of these antigens are different from each other, anti-VGLUT1 antibodies do not recognize VGLUT2, and vice versa (Figure 1 ). Pre-absorbed antibodies were prepared on incubation of antisera (50 l) with antigenic peptides (2 mg) on ice bath for 10 hr. Mouse monoclonal antibodies (MAbs) against glucagon, insulin, synaptophysin (SY38), serotonin, and acrosin (ACR-2) were obtained from Sigma (St Louis, MO), Progen (Heidelberg, Germany), NeoMarkers (Fremont, CA), and Monosan (Uden, The Netherlands), respectively. Rabbit polyclonal antibodies against gastrin and rat monoclonal antibodies against somatostatin were from Chemicon (Temecula, CA). Guinea pig polyclonal antisera against rat pancreatic polypeptide and PYY were from Linco Research (St Charles, MO) and Progen, respectively. Mouse MAbs against vesicular acetylcholine transporter (VAchT) were from Promega (Madison, WI). Goat polyclonal antibodies against GluR5 were from Santa Cruz Biotechnology (Santa Cruz, CA). Guinea pig polyclonal antibodies against the amino-terminal region of KA1 were kindly supplied by Dr. M. Morita (Tokyo College of Pharmacy, Japan). Dilution of the antibodies for indirect immunofluorescence microscopy is as follows: VGLUT1, 500; VGLUT2, 500; glucagon, 500,000; pancreatic polypeptide, 50; synaptophysin, 20, serotonin, 200; acrosin, 2000; gastrin, 200 ; somatostatin, 500; VAchT, 500; GluR5, 10; KA1, 10.
Expression of VGLUT1 and VGLUT2
Rat VGLUT2 cDNA, as previously described (Aihara et al. 2000) , was subcloned into the EcoRI site of expression vector pcDNA3.1 (Invitrogen; San Diego, CA). The resultant construct, VGLUT2-pcDNA3.1, was used to transfect COS7 cells by lipofection using Trans IT reagent (Mirus; Madison, WI). The expression vector for VGLUT1, VGLUT1-pcDNA3.1, was kindly supplied by Drs. S. Takamori and R. Jahn of Göttingen University (Germany). The COS7 cells were grown in DMEM containing 10% fetal calf serum, penicillin, and streptomycin in a humidified incubator at 37C with 5% CO 2 . After incubation for 24 hr in 10-cm dishes, VGLUT1-pcDNA3.1, VGLUT2-pcDNA3.1, or the pcDNA3.1 vector alone was transfected into COS7 cells by adding 12 g of the plasmid DNA per dish. After further incubation for 48 hr, the cells were rinsed with 10 ml of buffer comprising 20 mM MOPS-Tris (pH 7.0), 0.3 M sucrose, 2 mM Mg-acetate, 4 mM KCl, and protease inhibitors (leupeptin and pepstatin A at 10 g/ml each), and then disrupted by brief sonication for 30 sec at output 4 with a Tomy Ultrasonic Disruptor UD-200. Then the mixture was centrifuged at 10,000 ϫ g for 5 min and the resultant supernatant was centrifuged at 266,000 x g for 30 min in a Beckman Optima TLX ultracentrifuge. The precipitate was suspended in the same buffer, and used for Western analysis.
Specimens, Immunohistochemistry, and Immunoelectron Microscopy
Indirect immunofluorescence microscopy was performed as described previously, using an Olympus FV-300 confocal laser microscope . For immunoelectron microscopy, the LR White embedding immunogold method was used . Rats were anesthetized with ether and then perfused intracardially with saline, followed by 0.2% glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Then each pancreas or testis was cut into small pieces, washed with 0.1 M cacodylate buffer (pH 7.4), stained with uranyl acetate for 2 hr, dehydrated, and then embedded in LR White for 2 days at Ϫ 20C. Ultrathin sections on nickel grids were incubated with PBS containing 2% goat serum and 0.5% bovine serum albumin for 15 min, and then treated with either antibodies against VGLUT2 (diluted 1:50) or a mixture of antibodies against VGLUT2 (diluted 1:50) and pancreatic polypeptide (diluted 1:200) for 30 min. The sections were washed and treated with the secondary antibodies conjugated with colloidal gold. The sections were washed with 0.1 M cacodylate buffer, postfixed with 5% glutaraldehyde, stained sequentially with uranyl acetate for 30 min and lead citrate for 1 min, and observed under a Hitachi H-7100S electron microscope.
RT-PCR and Northern Analysis
Total RNA extracted from brain, islet of Langerhans, testis, and other tissues (1 g) was transcribed into cDNA as described previously . For PCR amplification, the 100-fold diluted synthesized cDNA solution was added to the reaction buffer containing 0.12 M dNTPs (30 M each dNTP), 25 pmole of primers, and 1.5 U of Gold Taq DNA polymerase (PE Biosystems; Urayasu, Japan). In the case of VGLUT1, the following primers were used: sense primer, AGTGAAATGGAAGACGAGGTT (1687-1717); antisense primer, TTCGGCACGAGCTTGAAACT (2002-2022) (GenBank no. U07609) (Ni et al. 1994 ). In the case of VGLUT2, the following primers were used; sense primer 2, AACACATCAACCAAGCAAGTC (2304-2324); antisense primer, AGGTAGTGAATGGGAGAGCA (2896-2915) (GenBank no. AF271235) (Aihara et al. 2000) . Thirty temperature cycles were conducted as follows: denaturation at 94C for 30 sec, annealing at 58C for 30 sec, and extension at 72C for 1 min. In the case of KA1 and GluR5, the primers used and conditions for amplification were described previously , which were AT-GACAAGACAGCTACTATC (703-722) as a sense primer and CCATTCCTGGTGAACTGTAA (1212-1231) as an antisense primer for KA1 (Werner et al. 1991) , and GGTC-CTCTATTACAACTGGA (523-544) as a sense primer and ATGCCATCCAGAAGACCAGT (959-978) as an antisense primer for GluR5 (Bettler et al. 1990 ). The amplification products were finally analyzed by polyacrylamide gel electrophoresis. DNA sequencing was performed by the chaintermination method (Sambrook et al. 1989) . For Northern analysis, mRNA (25 g) was purified with an OligoTexdT30 Super mRNA purification kit (Takara; Kusatsu, Japan) from total RNA (500 g) isolated from testis or other tissues. The mRNAs (5.0 g per lane) were separated on a formaldehyde agarose gel (1%) and then transferred to a nylon membrane (Amersham). The immobilized RNA was probed with cDNA fragments of VGLUT1 (bases 1687-2022), VGLUT2 (bases 2304-2915), KA1 (bases 703-1231), and GluR5 (bases 523-978), and labeled with [ 32 P]-dCTP (3000 Ci/mmol; Amersham) random priming. After extensive washing, the membrane was subjected to autoradiography using BAS 1000 film (Fuji Film; Fuji, Japan).
Other Procedures
Crude synaptic vesicles were prepared as described . Islets of Langerhans were isolated from male Wistar rats at 7-8 postnatal weeks by the collagenase digestion method combined with discontinuous Ficoll gradient centrifugation (Gotoh et al. 1987) . A membrane fraction of islets of Langerhans or testes was prepared as follows: 500 islets or 2 testes were homogenized with a Dounce homogenizer in 20 mM MOPS-Tris (pH. 7.5) containing 0.3 M sucrose, 5 mM EDTA, 5 g/ml pepstatin A, 5 g/ml leupeptin, 5 g/ml chymostatin, and 5 g/ml antipain. After removing nuclei and unbroken cells by centrifugation at 3000 ϫ g for 8 min, the supernatant was centrifuged at 100,000 ϫ g for 40 min and the resultant pellet was washed twice, suspended in the same buffer, and finally dissociated with the sample buffer containing 10% SDS and 10% ␤ -mercaptoethanol. Western blotting was performed as described previously .
Results
Specific Antibodies to VGLUT1 and VGLUT2
In this study we used site-specific polyclonal antibodies against VGLUT1 and VGLUT2, which were prepared using GST-fusion proteins containing the carboxyl terminals of these transporters. The regions used for the antibodies are different from each other (Ni et al. 1994; Aihara et al. 2000) . The VGLUT1 antibodies recognized a single polypeptide of ‫ف‬ 62 kD in brain membranes ( Figure 1A , Lane 1) and VGLUT1-expressing COS7 cell membranes ( Figure 1A , Lane 3), but not any polypeptide in the membrane fraction prepared from COS7 cells (control vector) ( Figure 1A , Lane 2) or VGLUT2-expressing COS7 cells ( Figure 1A , Lane 4). The immunoreactivity was blocked when the nitrocellulose sheet was treated with the antigenic peptide used for the preparation of anti-VGLUT1 antibodies during immunostaining ( Figure 1A , Lane 5). Conversely, antibodies against VGLUT2 specifically reacted with a 67-kD polypeptide in synaptic vesicle membranes and VGLUT2-expressing COS7 membranes ( Figure 1B , Lanes 1 and 2). No crossreactivity was observed in control COS7 membranes ( Figure 1B These results indicated that these antibodies specifically recognized VGLUT1 and VGLUT2, respectively.
Expression and Localization of VGLUTs in the Gastroenteropancreatic System
We explored the expression of VGLUT1 and VGLUT2 in peripheral tissues by indirect immunofluorescence microscopy and immunoelectron microscopy, and found that the major sites of VGLUT1 and VGLUT2 expression were in the gastroenteropancreatic system (see below).
Islets of Langerhans. It is unknown whether VGLUT1
is expressed in pancreatic polypeptide-containing F-cells. F-cells account for 5-6% of islet cells. Doublelabeling indirect immunofluorescence microscopy clearly indicated that essentially all pancreatic polypeptidecontaining cells express VGLUT1 immunoreactivity, indicating that F-cells express VGLUT1 (Figure 2 ). Double-labeling immunoelectron microscopy indicated that gold particles for VGLUT1 and VGLUT2 (arrowheads) were localized with pancreatic polypeptidecontaining secretory granules in F-cells ( Figure 3A and 3B). Quantitatively, the labeling densities for VGLUT1 in pancreatic polypeptide-containing secretory granules and other areas, including the cytoplasm and nuclei of F-cells, were 4.5 Ϯ 0.2 and 0.02 Ϯ 0.01 (number of immunogold particles/ m 2 ; four independent experiments), respectively. The labeling densities for VGLUT2 in pancreatic polypeptide-containing secretory granules and other areas, including the cytoplasm and nuclei, were 3.6 Ϯ 0.2 and 0.03 Ϯ 0.01 (number of immunogold particles/ m 2 ; four independent experiments), respectively. Double-labeling immunoelectron microscopy also indicated essentially no labeling of VGLUT1 or VGLUT2 and pancreatic polypeptide in ␤ -cells ( Figure 3C ) and ␦ -cells (data not shown). Therefore, both VGLUT1 and VGLUT2 are constituents of pancreatic polypeptide-containing secretory granules in F-cells.
Stomach and Small Intestine. In stomach, no VGLUT1 immunoreactivity was detected, whereas VGLUT2-positive cells were identified in the stomach mucosa, especially in the antrum and pylorus. Double-labeling immunohistochemistry indicated that VGLUT2-positive cells coincided with pancreatic polypeptide. Among 50 pancreatic polypeptide-containing cells tested, 31 cells (62%) expressed VGLUT2. Because pancreatic polypeptide and VGLUT2 are co-distributed throughout the cells, VGLUT2 appears to be associated with pancreatic polypeptide-containing secretory granules, as in the case of islet F-cells. In contrast, VGLUT2-positive cells did not coincide with glucagon-, somatostatin-, or serotonin-containing cells, obtained from more than 100 cells each (Figure 4) . Gastrin-contain-ing cells (G-cells) did not contain VGLUT2, obtained from more than 200 cells (Figure 4) . The pre-absorbed antibodies failed to immunostain any cells (Figure 4) .
As in the case of stomach, no VGLUT1 immunoreactivity was detected in the small intestine (data not shown). On the other hand, VGLUT2 immunoreactivity was frequently observed in the ileum. Figure 5 indicates that the VGLUT2 immunoractivity is always co-localized with that of glucagon, which was obtained from 80 cells. Preabsorbed VGLUT2 antibodies failed to immunostain glucagon-containing cells (data not shown). In contrast to islets of Langerhans and stomach, pancreatic polypeptide-containing cells (33 cells observed) did not contain any immunoreactivity for VGLUT2. Serotonin-containing cells (more than 100 cells) also did not contain any immunoreactivity for VGLUT2. Among enteroendocrine cells, L-cells showed glucagon immunoreactivity (Solcia et al. 1987) . Proglucagon is processed to glicentin in L cells (Holst 1997) . Pancreatic polypeptide-like peptide (PYY), which differs from authentic pancreatic polypeptide, was also present in secretory granules in most L-cells (Solcia et al. 1987) . Consistently, VGLUT2 immunoreactivity was also co-localized with PYY, which was obtained from 48 cells observed ( Figure 5 ). The VGLUT2-positive cells are located in the mucosal epithelium region near muscles and show a morphology distinct from the enteric neurons, and do not coincide with VAchT and synaptophysin, markers of glutamatergic enteric neurons (Tong et al. 2001) (Figure 6 ). Considering these findings, we concluded that the VGLUT2-expressing cells are L-cells. Co-association of VGLUT2 with glucagon and PYY with particles suggests that VGLUT2 is associated with glicentin-containing secretory granules in these cells, as in the case of glucagon-containing secretory granules in islet ␣ -cells.
Expression and Localization of VGLUT2 in Testis
Mammalian testes consist of many seminiferous tubules, in which the epithelial cells called Sertoli cells anchor and provide nourishment for the developing spermatozoa. The germ stem cells in each tubule reside at the tubule periphery and give rise to proliferating spermatogonial cells. Only the primitive spermatogonia undergo a series of synchronous cell divisions and differentiation, leading to mature sperm (see Figure 7) . Immunohistochemical evidence suggests that the immunoreactivity for NMDAR1, GluR2/3 or mGluR2/3 antibodies is distributed in various sites, including the sperm heads of spermatids and spermatozoa (Gill et al. 2000) , and that for mGluR5 and mGluR1 antibodies is found inside semiferous tubules and in mature spermatozoa, respectively (Storto et al. 2001 ). These observations prompted us to explore the expression of VGLUTs in testis.
RT-PCR and Northen blotting analysis clearly indicated the presence of a VGLUT2 gene transcript in testis (Figure 8 ), while the level of transcription of the VGLUT1 gene was below the detection limit of our assay (not shown). Western blotting analysis indicated the presence of VGLUT2 protein in the particulate fraction of testis (Figure 8 ). These results indicated the expression and localization of VGLUT2 in testis. Immunohistochemistry indicated that VGLUT2 immunoreactivity was specifically located in spermatids (Figure 7 ). This immunoreactivity disappeared when the antibodies were pre-absorbed with antigenic polypeptide (Figure 7) . No VGLUT2 immunoreactivity was observed in primitive spermatogonia or mature sperm. These results indicated that VGLUT2 is expressed in spermatids. Developmentally, the immunoreactivity appears at 3 postnatal weeks, reaches a plateau at 7 weeks, and then gradually decreases, although some immunoreactivity remains even after 1 year. Consistent with the results of RT-PCR and Northern blotting analysis, little immunoreactivity for VGLUT1 was observed throughout a cross-section of testis (data not shown).
More detailed localization of VGLUT2 at the subcellular level was conducted as follows. We found that VGLUT2 immunoreactivity is always closely localized with acrosin, a marker for acrosomal protein in spermatids (Peknicova and Moos 1990) , indicating that VGLUT2 is in some way associated with the acrosomal membrane (Figure 9 ). Consistently, immunoelectron microscopy demonstrated that gold particles for VGLUT2 are associated with the outer acrosomal membrane ( Figure 10A, arrows) . A lower level of labeling by the VGLUT2 gold particles was observed in the acrosomal membranes of late spermatids ( Figure  10B ). Furthermore, only background labeling was observed in acrosomes of mature sperm ( Figure 10C ) compared with the labeling with control IgG ( Figure  10D ). From these results, we conclude that VGLUT2 is present in the outer acrosomal membrane.
The presence of VGLUT2 in the outer acrosomal membrane suggests that the acrosome is the site of l-glutamate accumulation. To reveal the glutamatergic system in spermatids in more detail, we investigated the expression and localization of glutamate receptors. Among various ionotropic glutamate receptors examined, we detected the expression of mRNA of KA1 and GluR5 on RT-PCR as well as Northern analysis ( Figures 11A and 11B) . Immunohistochemistry indicated that both KA1 and GluR5 are co-localized, suggesting the formation of a functional holoreceptor complex (Figure 12) , as in the case of the kainate receptor in neurons (Herb et al. 1992; Sakimura et al. 1992) . Interestingly, in spermatids, KA1 and GluR5 appear to be associated with the inner acrosomal cup structure facing the nucleus, a countersite for the presence of VGLUT2 (Figures 12 and 13, upper panels) . The localizations of KA1 and GluR5 seem to be elongated along with the acrosome in late spermatids, and remain in mature sperm (Figures 12 and 13 , lower panels), whereas VGLUT2 immunoreactivity is associated with the center of the acrosome (Figure 13 , lower panel). Taken together, these findings strongly suggest that the acrosome is the site of occurrence and reception of l-glutamate signal and that l-glutamate signaling may change during spermatogenesis.
Discussion
VGLUT confers the glutamatergic phenotype on neurons and some endocrine cells. Either VGLUT1 or VGLUT2 or both are expressed in almost all glutamatergic neurons. Although VGLUTs are greatly homologous to each other, their primary amino acid sequences exhibit 90% identity, the properties of the transporters, e.g. substrate specificity, chloride anionsensitivity, and driving force, are almost identical (Bellocchio et al. 2000; Takamori et al. 2000 Takamori et al. ,2001 Takamori et al. ,2002 Fremeau et al. 2001; Hayashi et al. 2001; Kaneko and Fujiyama 2002; Varoqui et al. 2002) . Recent results from our laboratory constituted the evidence for the functional occurrence of VGLUT1 and VGLUT in peripheral tissues. To completely characterize peripheral glutamatergic systems, in the present study we explored the expression and localization of VGLUT1 and VGLUT2 in peripheral tissues.
We found that VGLUT1 and VGLUT2 are expressed in the gastroenteropancreatic tract and testis. In pancreas, VGLUT2 is present in glucagon-containing secretory granules in ␣-cells (Hayashi et al. . The PCR product of the expected size is indicated by an arrow. The PCR product was not detected if reverse transcriptase was omitted from the reaction mixture. The apparent molecular mass is also shown (Lane 1). (Center) Northern analysis of the presence of mRNA in brain (Lane 1) and testis (Lane 2), as indicated, followed by probing with the PCR product amplified from VGLUT2, as described in the text. As a loading control, hybridization with probes specific for G3PDH transcripts was performed for the same RNA blots (lower panel). (Right) Western blotting analysis. Membrane fractions of crude synaptic vesicles (Lane 1) and testis (Lane 2) (50 g of protein each) were solubilized with sample buffer containing 10% SDS and then subjected to 10% SDS-PAGE. Then the proteins were transferred to nitrocellulose sheets. Western blotting was performed using the indicated antibodies and the immunoreactivity was visualized by ECL. The apparent molecular masses are also shown. 2001, 2003) and in pancreatic polypeptide-containing secretory granules in F-cells (Figure 2 ). VGLUT1 is also expressed and localized in pancreatic polypeptide-containing secretory granules in F-cells (Figure 2 ) and in glucagon-containing secretory granules in a subset of ␣-cells . The localization of VGLUT1 and VGLUT2 in these secretory granules implies that l-glutamate is co-sequestered with glucagon and pancreatic polypeptide in these secretory granules and is co-secreted under low-glucose conditions. In fact, we recently found that lowglucose conditions triggered co-secretion of l-glutamate and glucagon from isolated islets and from ␣TC6, clonal ␣-cells (Yamada et al. 2001) . Therefore, pancreatic polypeptide may be co-secreted with l-glutamate under low-glucose conditions. The released l-glutamate in turn binds to the glutamate receptors in neighboring islet cells, causing a glutamatergic response. In ␤-cells, stimulation of glutamate receptors triggers selective secretion of GABA through the enhanced exocytosis of synapselike microvesicles . In ␣-cells, l-glutamate may act as an autocrine or paracrine signaling molecule, inhibiting exocytosis of glucagon and l-glutamate via a metabotropic receptor (mGluR8) (Tong et al. 2002) . Therefore, the glutamatergic system may be involved, at least partly, in a regulatory mechanism for glucagon secretion. The glutamatergic system in islets of Langerhans is the first example of secretory granule-mediated glutamate signal transmission.
Various endocrine cells may receive signals in the GI tract and transmit them to a local target, such as neighboring epithelial cells, subepithelial nerve endings, and smooth muscle fiber. Glicentin may act as an intercellular messenger in paracrine action (Solcia et al. 1987) . Glucagon-like peptide also potently inhibits GI secretion and motility, and its physiological functions include mediation of the "ileal brake" effect, which regulates food intake (Holst 1997) . Pancreatic polypeptide and its relative, PYY, have an effect similar to that of glucagon (Solcia et al. 1987) . We have shown that VGLUT2 is expressed in a subpopulation of pancreatic polypeptide-containing cells in stomach and in glucagon-like immunoreactivity and PYY-containing cells in small intestine, which is obviously different from glutamatergic enteric neurons. The co-localization of VGLUTs with either glucagon, glicentin, pancreatic polypeptide, or PYY supports the possibility that l-glutamate is co-released with these peptides. Thus, as in the case of islets of Langerhans, l-glutamate may regulate endocrine function in the GI tract. Other endocrine cells, such as D-cells and enterochromaffin cells, lack VGLUT, suggesting the absence of l-glutamate secretion in these cells. It is noteworthy that VGLUT2 is present in pancreatic polypeptide-containing cells but not in glucagon-containing cells in stomach, wheras VGLUT2 is present in glucagon and PYY-containing cells but not in pancreatic polypeptide-containing cells in small intestine. The different expression of VGLUT2 suggests the different roles of l-glutamate in cell-to-cell interactions in these organs. The mode of glutamate signal output can be classified into two major types, i. e., vesicle-dependent and vesicle-independent processes. The present study, and our or other recent studies, clearly indicated that vesicle-dependent glutamate signal output can be further classified into at least three groups, i.e., exocytosis of synapse vesicles in neurons, exocytosis of synapse-like microvesicles in pinealocytes, and exocytosis of hormone-containing secretory granules. Astrocytes are also known to secrete l-glutamate in a Ca 2ϩ -dependent manner (Purpura et al. 1994) , although the secretory mechanism in glia has not yet been characterized. The expression and localization of VGLUT2 in testis may reflect unexpected features of glutamatergic signal output systems.
In testis, VGLUT2 is present in the outer surface of the acrosomal membrane. This implies that l-glutamate is accumulated in acrosomes through VGLUT2. Acrosomes are specialized lysosome-like organelles located in the heads of sperm cells that contain a rich store of hydrolytic enzymes, whose activity plays an essential role in fertilization. During progression of the acrosomal reaction, fusion of the plasma membrane and outer acrosomal membrane allows release of the acrosomal contents. After the detachment of these membrane structures, the inner acrosomal membrane covers the heads of sperm. The internal pH is maintained acidic by active entry of protons through vacuolar proton ATPase (Lee et al. 1983 ; reviewed in Nelson and Harvey 1999; Kawa et al. 2000) , which may provide the driving force for the active transport of l-glutamate, leading to its accumulation. Therefore, it is possible that acrosomes store l-glutamate. Because KA1 and GluR5, components of functional kainate receptor, are expressed and co-localized in the outer acrosomal membrane, it is possible that l-glutamate enters through the outer acrosomal membrane and then binds to the kainate receptor at the inner membrane of acrosomes, causing the glutamatergic response. In this hypothesis, l-glutamate may function as an intracellular messenger, and this type of signaling is no longer "paracrine" or "autocrine" but most probably "intracrine," as proposed for the signal Figure 11 Expression and localization of KA1 and GluR5 glutamate receptors in testis. (A) RT-PCR detection of transcripts of KA1 and GluR5 in brain (Lane 1) and testis (Lane 2). The expected size of each PCR product is indicated. PCR product was not detected if reverse transcriptase was omitted from the reaction mixture. (B) Detection of KA1 and GluR5 mRNA by Northern blotting analysis. mRNAs from brain (Lane 1) and testis (Lane 2) were probed with the PCR products amplified from KA1 and GluR5, as described above. As a loading control, hybridization of probes specific for G3PDH transcripts was performed for the same RNA blots (lower panel). Size markers are also included.
Figure 12
Co-localization of KA1 (green) and GluR5 (red) in early spermatids (upper panels) and late spermatids (bottom panels). Note that KA1 and GluR5 are elongated along with acrosomes in late spermatids and mature sperm. Bars ϭ 10 m.
Figure 13
Immunohistochemical localization of KA1 and VGLUT2. Sections of testis were doubly immunostained with antibodies against VGLUT2 (red) and KA1 (green) and were observed under a confocal microscope. Merged pictures are also shown. Bars ϭ 10 m. transmission of some hormones, including steroid hormones (reviewed in Re 2002) .
Alternatively, as to the function of acrosomal l-glutamate, it has been shown that glutamate decarboxylase (GAD), which synthesizes GABA from l-glutamate, is expressed in acrosomes, and that the GABA B receptor is present on the acrosomal membrane (He et al. 2001; Hu and Yan 2002) . These proteins involved in the GABAergic systems in testis appear during the maturation of spermatids together with the disappearance of VGLUT2. Therefore, VGLUT2 might be involved in supplying l-glutamate for the synthesis of GABA in acrosomal regions. These possibilities are now under investigation in our laboratory.
Very recently, another VGLUT isoform, VGLUT3, has been identified (Fremeau et al. 2002; Gras et al. 2002; Schafer et al. 2002; Takamori et al. 2002) . In central nervous system, VGLUT3 shows more restricted expression and is present in some populations of inhibitory neurons, cholinergic interneurons, monoamine neurons, and glia. VGLUT3 is also expressed in liver and kidney (Fremeau et al. 2002) . It is therefore quite likely that VGLUT3 functions as a component of peripheral glutamatergic systems. Further studies, particularly expression and localization of VGLUT3, are required to elucidate the overall features of the peripheral glutamatergic system.
In conclusion, the present work has demonstrated the expression of VGLUT1 and VGLUT2 in the gastroenteropancreatic system and testis. The localization of VGLUT1 and VGLUT2 in secretory granules in the gastroenteropancreatic system suggests a widespread role of l-glutamate as an intercellular messenger. The localization of VGLUT and glutamate receptors in spermatids suggests the role of l-glutamate as an intracellular messenger. We can pressume that the modes of action of l-glutamate signal transmission are much more varied than was previously believed.
